Microbiotica
The company’s platform links patient phenotypes to strain-level microbiome analysis to accelerate the availability of novel therapeutics. It is a global leader in gut bacterial culturing and has a world-leading microbiome culture collection, a proprietary Reference Genome Database, and advanced microbiome bioinformatics.
In Q1 2022, Microbiotica secured the largest microbiome financing in Europe to date with its £50 million ($67 million) series B raise to support its Phase 1b immuno-oncology and ulcerative colitis clinical trials.
In November 2024, Microbiotica said the first patient had been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This followed last month’s announcement that the first patient has been dosed in its advanced melanoma (MELODY-1) trial.
Microbiotica’s investors and supporters include British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners and Tencent.
